Nuclea Tech, Boston Medical Center Partner on Cancer Gene Expression Biomarkers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nuclea Technologies today announced a deal with Boston Medical Center for the discovery of new gene expression biomarkers to diagnose cancer.

Under the partnership, research will be directed at gene expression in specific tumors to help radiologists "review results in a different and more comprehensive way," Nuclea said in a statement.

Based in Pittsfield, Mass., Nuclea discovers and develops genetic, protein, and antibody biomarkers and diagnostic assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.